Literature DB >> 17564995

Epidemiology of infection and colonization with vancomycin-resistant enterococci and frequency of cocolonization with methicillin-resistant Staphylococcus aureus in children.

Lacey Benson1, Bruce Sprague, Joseph Campos, Nalini Singh.   

Abstract

We report the descriptive and molecular epidemiology of vancomycin-resistant enterococci (VRE) infection and colonization and cocolonization with methicillin-resistant Staphylococcus aureus (MRSA) in children. Interunit and intraunit spread of VRE was detected, and 8 cases of VRE-MRSA cocolonization were identified. Seven of these cases were identified only via active surveillance, because clinical evidence of VRE colonization was absent.

Entities:  

Mesh:

Year:  2007        PMID: 17564995     DOI: 10.1086/518454

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  3 in total

1.  Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus.

Authors:  Katherine Reyes; Rushdah Malik; Carol Moore; Susan Donabedian; Mary Perri; Laura Johnson; Marcus Zervos
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

2.  Determining the clinical significance of co-colonization of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in the intestinal tracts of patients in intensive care units: a case-control study.

Authors:  Young Kyung Yoon; Min Jung Lee; Yongguk Ju; Sung Eun Lee; Kyung Sook Yang; Jang Wook Sohn; Min Ja Kim
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-10-10       Impact factor: 3.944

3.  Low colonization rates with Multidrug-resistant Gram-negative bacteria in a German hospital-affiliated hemodialysis center.

Authors:  Ralph Wendt; Olaf Nickel; Almut Botsch; Margareta Lindner; Angela Bethge; Kathrin Marx; Bernhard R Ruf; Joachim Beige; Christoph Lübbert
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.